DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 3, 2005; DOI: 10.1124/dmd.104.003087


0090-9556/05/3311-1648-1656$20.00
DMD 33:1648-1656, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.003087v1
33/11/1648    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zwickenpflug, W.
Right arrow Articles by Richter, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zwickenpflug, W.
Right arrow Articles by Richter, E.

METABOLISM OF MYOSMINE IN WISTAR RATS

Wolfgang Zwickenpflug, Stefan Tyroller, and Elmar Richter

Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians University, Munich, Germany

The alkaloid myosmine is present not only in tobacco products but also in various foods. Myosmine is easily nitrosated, yielding 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) and the esophageal tobacco carcinogen N'-nitrosonornicotine. Due to its widespread occurrence, investigations on the metabolism and activation of myosmine are needed for risk assessment. Therefore, the metabolism of myosmine has been studied in Wistar rats treated with single oral doses of [pyridine-5-3H]myosmine at 0.001, 0.005, 0.5, and 50 µmol/kg body weight. Oral administration was achieved by feeding a labeled apple bite. Radioactivity was completely recovered in urine and feces within 48 h. At the two lower doses, 0.001 and 0.005 µmol/kg, a higher percentage of the radioactivity was excreted in urine (86.2 ± 4.9% and 88.9 ± 1.7%) as compared with the higher doses, 0.5 and 50 µmol/kg, where only 77.8 ± 7.3% and 75.4 ± 6.6% of the dose was found in urine. Within 24 h, urinary excretion of radioactivity was nearly complete with less than 4% of the total urinary output appearing between 24 and 48 h. The two major metabolites accounting for >70% of total radioactivity in urine were identified as 3-pyridylacetic acid (20–26%) and 4-oxo-4-(3-pyridyl)butyric acid (keto acid, 50–63%) using UV-diode array detection and gas chromatography-mass spectrometry measurements. 3-Pyridylmethanol (3–5%), 3'-hydroxymyosmine (2%) and HPB (1–3%) were detected as minor metabolites. 3'-Hydroxymyosmine is exclusively formed from myosmine and therefore might be used as a urinary biomarker for myosmine exposure in the future.


Address correspondence to: Dr. Wolfgang Zwickenpflug, Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians University, Goethestrasse 33, D-80336 Munich, Germany. E-mail: wolfgang.zwickenpflug{at}lrz.uni-muenchen.de







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.